

Table S1. Odds ratio (OR) and 95% confidence interval (CI) of clinical status and *HMGB1* rs1045411 genotypic frequencies in 324 HCC patients.

Variable	Genotypic frequencies			p value
	CC (N=223)	CT+TT (N=101)	OR (95% CI)	
Clinical Stage				
Stage I/II	148 (66.4%)	66 (65.3%)	1.00	p=0.857
Stage III/IV	75 (33.6%)	35 (34.7%)	1.046 (0.638-1.717)	
Tumor size				
≤ T2	150 (67.3%)	67 (66.3%)	1.00	p=0.869
> T2	73 (32.7%)	34 (33.7%)	1.043 (0.633-1.717)	
Lymph node metastasis				
No	216 (96.9%)	97 (96.0%)	1.00	p=0.705
Yes	7 (3.1%)	4 (4.0%)	1.272 (0.364-4.448)	
Distant metastasis				
No	211 (94.6%)	95 (94.1%)	1.00	p=0.839
Yes	12 (5.4%)	6 (5.9%)	1.111 (0.405-3.047)	
Vascular invasion				
No	181 (81.2%)	86 (85.1%)	1.00	p=0.383
Yes	42 (18.8%)	15 (14.9%)	0.752 (0.395-1.430)	
Child-Pugh grade				
A	171 (76.7%)	75 (74.3%)	1.00	p=0.636
B or C	52 (23.3%)	26 (25.7%)	1.140 (0.662-1.963)	
HBsAg				
Negative	128 (57.4%)	59 (58.4%)	1.00	p=0.864
Positive	95 (42.6%)	42 (41.6%)	0.959 (0.596-1.545)	
Anti-HCV				
Negative	122 (54.7%)	49 (48.5%)	1.00	p=0.301
Positive	101 (45.3%)	52 (51.5%)	1.282 (0.800-2.053)	
Liver cirrhosis				
Negative	45 (20.2%)	20 (19.8%)	1.00	p=0.937
Positive	178 (79.8%)	81 (80.2%)	1.024 (0.568-1.844)	

The ORs with analyzed by their 95% CIs were estimated by logistic regression models.
 > T2: multiple tumor more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s)